Empagliflozin versus dapagliflozin in heart failure
Abstract
No clinical trial has compared head-to-head the effects of empagliflozin and dapagliflozin in patients with heart failure.
To compare the risk of heart failure rehospitalization or all-cause death between initiators of empagliflozin and dapagliflozin in patients with heart failure.
This new-user, active-comparator cohort study used nationwide Danish healthcare data to emulate a hypothetical target trial that would compare the risk of heart failure rehospitalization or all-cause death in adults with heart failure initiating empagliflozin (intervention) or dapagliflozin (comparator) (Figure 1). Patients were identified from the Danish Heart Failure Registry, which enrolls patients at their first-time hospital contact with heart failure, meeting the European Society of Cardiology criteria. The primary outcome was a composite of heart failure rehospitalization and all-cause death, while secondary outcomes included each component separately. Heart failure rehospitalization was identified from the Danish National Patient Registry and all-cause death from the Danish Civil Registration System. In intention-to-treat analyses, cumulative incidences were estimated using the Aalen-Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazards regression. Follow-up began at treatment initiation (June 1, 2014–December 31, 2022) and continued until the first occurrence of an outcome, emigration, or study end (December 31, 2022). Baseline covariates (n=66) were…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 6,264 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.